STOCK TITAN
  1. Home
  2. Sec-filings
  3. GDRX
  4. [8-K] GoodRx Holdings, Inc. Reports Material Event

GoodRx posts Q2 2026 results, lifts guidance

GoodRx Holdings reported Q2 2026 revenue of $200.4 million, down 1% from $203.1 million a year earlier, as its business mix shifted.

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

GoodRx Holdings reported Q2 2026 revenue of $200.4 million, down 1% from $203.1 million a year earlier, as its business mix shifted. Prescription transactions revenue fell 26% to $106.4 million on fewer Monthly Active Consumers, broader retail pharmacy changes, lower unit economics and a deliberate pivot of product and marketing spend toward newer subscription offerings.

Subscription revenue rose 39% to $28.5 million and Pharma Direct revenue increased 76% to $61.6 million, helped by condition‑specific subscriptions, including weight loss, and GLP‑1 access programs. Net income was $8.5 million versus $12.8 million, with Adjusted EBITDA of $63.7 million and a 31.8% margin. Operating cash flow strengthened to $80.8 million. As of June 30, 2026, cash and cash equivalents were $296.1 million and total debt $492.5 million. Monthly Active Consumers averaged 5.0 million, while subscription plans grew to 764,000. Management raised full‑year 2026 guidance to revenue of $790–$805 million, a (1%) to 1% year‑over‑year change versus 2025 revenue of $796.9 million, and Adjusted EBITDA of $240–$250 million.

Positive

  • None.

Negative

  • None.

Filing Explained

Six-month results include Class A repurchases, alongside cash and debt at June 30.

As a Form 8-K, this report discloses GoodRx’s completed second-quarter results and updated full-year outlook; it also records Class A common-stock repurchases during the six months ended June 30, 2026, a cash allocation affecting the company’s common-stock capital structure.

At June 30, 2026, the company reported cash and cash equivalents against total debt; six-month operating cash flow was positive, while investing and financing activities used cash, respectively.

The financing statement separately reports employee taxes paid in connection with net share settlement of equity awards, so the disclosed equity-related cash uses include both repurchases and employee tax settlements.

The raised Adjusted EBITDA guidance remains an expectation rather than a realized result, and the filing states that it is a non-GAAP measure that was not reconciled to GAAP because of uncertainty in the reconciling items.

Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Q2 2026 Revenue $200.4 million Revenue decreased 1% from $203.1 million in the prior-year quarter
Q2 2026 Net Income $8.5 million Net income margin was 4.3% compared to 6.3% a year earlier
Q2 2026 Adjusted EBITDA $63.7 million Adjusted EBITDA Margin was 31.8% versus 34.2% in the prior-year quarter
Q2 2026 Pharma Direct Revenue $61.6 million Pharma Direct revenue increased 76% year-over-year from $35.0 million
Q2 2026 Subscription Revenue $28.5 million Subscription revenue increased 39% year-over-year from $20.5 million
Q2 2026 Operating Cash Flow $80.8 million Net cash provided by operating activities in the second quarter of 2026
Cash and Cash Equivalents $296.1 million Balance as of June 30, 2026
FY 2026 Revenue Guidance $790 - $805 million Guidance range implies (1%) to 1% year-over-year change vs 2025 revenue of $796.9 million
Adjusted EBITDA financial
"Adjusted EBITDA1 of $63.7 million; Adjusted EBITDA Margin1 of 31.8%"
Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.
Monthly Active Consumers financial
"Monthly Active Consumers (MACs) refers to the number of unique consumers who have used a GoodRx code"
GLP-1 access programs medical
"in particular our GLP-1 access programs, which are part of our consumer direct pricing"
Revenue $200.4 million Revenue decreased 1% from $203.1 million in the prior-year quarter
Net income $8.5 million Down from $12.8 million in the prior-year quarter
Adjusted EBITDA $63.7 million Compared to $69.4 million in the prior-year quarter
Net cash provided by operating activities (Q2) $80.8 million Up from $49.6 million in the comparable period last year
Pharma Direct revenue $61.6 million Increased 76% year-over-year from $35.0 million
Guidance

Full-year 2026 revenue guidance of $790–$805 million, implying (1%) to 1% year-over-year change versus 2025 revenue of $796.9 million, and Adjusted EBITDA guidance of $240–$250 million.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were GoodRx (GDRX) Q2 2026 revenue and net income?
GoodRx reported Q2 2026 revenue of $200.4 million and net income of $8.5 million. Revenue decreased 1% from $203.1 million a year earlier, while net income declined from $12.8 million, reflecting lower prescription transactions revenue and a shifting business mix.

How did GoodRx (GDRX) Pharma Direct and subscription businesses perform in Q2 2026?
In Q2 2026, Pharma Direct revenue rose to $61.6 million, a 76% year-over-year increase, while subscription revenue grew to $28.5 million, up 39%. Growth was driven by expanded manufacturer relationships and condition-specific subscription programs, particularly weight loss offerings and GLP-1 access programs.

What full-year 2026 guidance did GoodRx (GDRX) provide?
GoodRx raised full-year 2026 revenue guidance to $790–$805 million, versus 2025 revenue of $796.9 million, implying a (1%) to 1% year-over-year change. The company also guided to $240–$250 million of Adjusted EBITDA for 2026, increasing its profitability expectations.

What is GoodRx (GDRX) cash, debt, and operating cash flow position as of June 30, 2026?
As of June 30, 2026, GoodRx held $296.1 million in cash and cash equivalents and had total outstanding debt of $492.5 million. Q2 2026 net cash provided by operating activities was $80.8 million, up from $49.6 million in the comparable period of the prior year.

How are GoodRx (GDRX) subscription plans and key operating metrics evolving?
Subscription plans reached 764,000 as of June 30, 2026, up from 668,000 a year earlier, reflecting expansion of GoodRx Gold and condition-specific programs. Monthly Active Consumers averaged 5.0 million, while non-GAAP metrics showed Adjusted Net Income of $26.8 million and Adjusted EBITDA of $63.7 million.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
0001809519FALSE2701 Olympic BoulevardSanta MonicaCalifornia00018095192026-08-052026-08-05
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
________________________________________
FORM 8-K
________________________________________
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): August 5, 2026
________________________________________
GoodRx Holdings, Inc.
(Exact Name of Registrant as Specified in its Charter)
________________________________________
Delaware
001-39549
47-5104396
(State or Other Jurisdiction
of Incorporation)
(Commission File Number)
(IRS Employer
Identification No.)
2701 Olympic Boulevard
Santa Monica, California
90404
(Address of Principal Executive
Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: (855) 268-2822
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol(s)
Name of each exchange on which registered
Class A Common Stock, $0.0001 par value per
share
GDRX
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act
of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition
period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the
Exchange Act. ☐
Item 2.02    Results of Operations and Financial Condition.
On August 5, 2026, GoodRx Holdings, Inc. (the “Company”) announced the Company’s financial results for the three and six
months ended June 30, 2026. The full text of the press release issued in connection with the announcement is furnished as
Exhibit 99.1 to this report.
The information in Item 2.02 and Exhibit 99.1 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of
that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or
the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01    Financial Statements and Exhibits.
(d)Exhibits.
99.1*
Press Release, dated August 5, 2026.
104
Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.
*Furnished herewith.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned thereunto duly authorized.
GOODRX HOLDINGS, INC.
Date:
August 5, 2026
By:
/s/ Christopher McGinnis
Christopher McGinnis
Chief Financial Officer & Treasurer
Exhibit 99.1
a1a.jpg
GOODRX REPORTS SECOND QUARTER 2026 RESULTS
Pharma Direct and Subscription Revenue Increased 76% and 39%, Respectively, Year-Over-Year
Company Raises Full-Year 2026 Revenue and Adjusted EBITDA Expectations
SANTA MONICA, Calif. -- (August 5, 2026) -- GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," “GoodRx,” or the
“Company”), the leading platform for medication savings in the U.S., has released its financial results for the second quarter
of 2026.
Second Quarter 2026 Highlights
•Revenue of $200.4 million
•Net income of $8.5 million; Net income margin of 4.3%
•Adjusted Net Income1 of $26.8 million; Adjusted Net Income Margin1 of 13.4%
•Adjusted EBITDA1 of $63.7 million; Adjusted EBITDA Margin1 of 31.8%
•Net cash provided by operating activities of $80.8 million
“We entered 2026 focused on scaling Pharma Direct and subscriptions, and the second quarter provided clear evidence that
those investments are translating into stronger performance,” said Wendy Barnes, President and Chief Executive Officer of
GoodRx. “We believe this progress is accelerating our return to growth and strengthening the long-term durability of
GoodRx.”
1.Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Income, and Adjusted Net Income Margin are non-GAAP financial measures and are presented for
supplemental informational purposes only. Adjusted EBITDA Margin and Adjusted Net Income Margin are defined as Adjusted EBITDA and Adjusted Net
Income, respectively, divided by Adjusted Revenue. Refer to the Non-GAAP Financial Measures section below for definitions, additional information, and
reconciliations to the most directly comparable GAAP measures.
Second Quarter 2026 Financial Overview (all comparisons are made to the same period of the prior year unless otherwise
noted):
Revenue decreased 1% to $200.4 million compared to $203.1 million.
Prescription transactions revenue decreased 26% to $106.4 million compared to $143.1 million, primarily driven by a
decrease in the number of our Monthly Active Consumers due to the broader changes in the retail pharmacy landscape
including store closures and volume reduction in one of our integrated savings programs, as well as the deliberate shift of
product and marketing investment toward our new subscription offerings. The year-over-year decrease was also due to
lower unit economics which we expect to continue in the near-term as we made deliberate decisions to favor long-term
durability and certainty.
Subscription revenue increased 39% to $28.5 million compared to $20.5 million, primarily driven by the expansion and
growth of our condition-specific subscription programs, in particular weight loss, as well as a resulting increase in the
number of subscription plans.
Pharma Direct revenue increased 76% to $61.6 million compared to $35.0 million, driven by organic growth as we continued
to expand our market penetration with pharma manufacturers and other customers, in particular our GLP-1 access
programs, which are part of our consumer direct pricing.
Net income was $8.5 million compared to $12.8 million. Net income margin was 4.3% compared to 6.3%. Adjusted Net
Income1 was $26.8 million compared to $33.9 million.
Adjusted EBITDA1 was $63.7 million compared to $69.4 million. Adjusted EBITDA Margin1 was 31.8% compared to 34.2%.
Cash Flow and Capital Allocation
Net cash provided by operating activities in the second quarter was $80.8 million compared to $49.6 million in the
comparable period last year. As of June 30, 2026, we had cash and cash equivalents of $296.1 million and total outstanding
debt of $492.5 million.
We are focused on a disciplined approach to capital allocation, centered on furthering our mission and creating stockholder
value. Our capital allocation priorities are investing for profitable growth, paying down debt, buying back shares, and M&A
that aligns with our strategic priorities. These capital allocation priorities support our long-term growth strategy while also
providing flexibility to navigate near-term challenges.
Exhibit 99.1
a1a.jpg
Guidance
Management is raising its full-year 2026 guidance as follows:
$ in millions
FY 2026
FY 2025
YoY Change
Revenue
$790 - $805
$796.9
(1%) - 1%
Adjusted EBITDA2
$240 - $250
“We exceeded our expectations in the second quarter, with Pharma Direct revenue increasing 76% year-over-year and
subscription revenue increasing 39% year-over-year,” said Justin Fengler, incoming Chief Financial Officer and current Chief
Strategy & Operations Officer of GoodRx. “Based on our strong first-half performance, we are raising our full-year revenue
and Adjusted EBITDA guidance.”
2.Adjusted EBITDA is a non-GAAP financial measure and is presented for supplemental informational purposes only. We have not reconciled our Adjusted
EBITDA guidance to GAAP net income or loss because we do not provide guidance for such GAAP measure due to the uncertainty and potential variability of
stock-based compensation expense, acquired intangible assets and related amortization and income taxes, which are reconciling items between Adjusted
EBITDA and the most directly comparable GAAP measure. Because such items cannot be provided without unreasonable efforts, we are unable to provide a
reconciliation of the non-GAAP financial measure guidance to the corresponding GAAP measure. However, such items could have a significant impact on our
future GAAP net income or loss.
Investor Conference Call and Webcast
GoodRx management will host a conference call and webcast tomorrow, August 6, 2026, at 5:00 a.m. Pacific Time (8:00
a.m. Eastern Time) to discuss the results and the Company’s business outlook.
To access the conference call, please pre-register using the following link:
https://register-conf.media-server.com/register/BI2d7e976f9edd481db1351e5bb1902f6a
Registrants will receive a confirmation with dial-in details and a unique passcode required to join.
The call will also be webcast live on the Company’s investor relations website at https://investors.goodrx.com, where
accompanying materials will be posted prior to the conference call.
Approximately one hour after completion of the live call, an archived version of the webcast will be available on the
Company’s investor relations website at https://investors.goodrx.com for at least 30 days.
Exhibit 99.1
a1a.jpg
About GoodRx
GoodRx is the leading platform for medication savings in the U.S., used by nearly 25 million consumers and over one million
healthcare professionals annually. Uniquely situated at the center of the healthcare ecosystem, GoodRx connects
consumers, healthcare professionals, payers, pharmacy benefit managers, pharmaceutical manufacturers, and retail
pharmacies to make saving on medications easier. By reducing friction and inefficiencies, GoodRx helps consumers save
time and money when filling prescriptions so they can get the care they deserve. Since 2011, GoodRx has helped
Americans save over $100 billion on the cost of their medications.
GoodRx periodically posts information that may be important to investors on its investor relations website at https://
investors.goodrx.com. We intend to use our website as a means of disclosing material non-public information and for
complying with our disclosure obligations under Regulation FD. Accordingly, investors and potential investors are
encouraged to consult GoodRx’s website regularly for important information, in addition to following GoodRx’s press
releases, filings with the Securities and Exchange Commission and public conference calls and webcasts. The information
contained on, or that may be accessed through, GoodRx’s website is not incorporated by reference into, and is not a part of,
this press release.
Investor Contact
GoodRx
Aubrey Reynolds
ir@goodrx.com
Press Contact
GoodRx
Lauren Casparis
lcasparis@goodrx.com
Exhibit 99.1
a1a.jpg
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of
1995. All statements contained in this press release that do not relate to matters of historical fact should be considered
forward-looking statements, including without limitation statements regarding our future results of operations and financial
position, industry and business trends, including uncertainty in the macro environment, the impact of trends impacting retail
pharmacies on our future financial results, the potential impact of the new government-sponsored direct-to-consumer
platform called “TrumpRx.gov” (“TrumpRx”) and other evolving federal initiatives on our business, our value proposition, our
business strategy and our ability to execute on our strategic priorities including expanding manufacturer partnerships,
growing differentiated subscription offerings and strengthening retail relationships, our plans, market opportunity, ability to
preserve margin strength and long-term growth prospects, our capital allocation priorities, Pharma Direct as the future key
growth driver of our business, and the future of prescription access. These statements are neither promises nor guarantees,
but involve known and unknown risks, uncertainties and other important factors that may cause our actual results,
performance or achievements to be materially different from any future results, performance or achievements expressed or
implied by the forward-looking statements, including, but not limited to, risks related to our limited operating history and early
stage of growth; our recent growth rates may not be sustainable or indicative of future growth; our ability to achieve broad
market education and change consumer purchasing habits; our general ability to continue to attract, acquire and retain
consumers in a cost-effective manner; our significant reliance on our prescription transactions offering and ability to expand
our offerings; changes in medication pricing and the significant impact of pricing structures negotiated by industry
participants; our general inability to control the categories and types of prescriptions for which we can offer savings or
discounted prices; our reliance on a limited number of industry participants, including pharmacy benefit managers,
pharmacies, and pharma manufacturers; the competitive nature of our industry; risks related to pandemics, epidemics, or
outbreak of infectious disease; the accuracy of our estimate of our addressable market and other operational metrics; our
ability to respond to changes in the market for prescription pricing and to maintain and expand the use of GoodRx codes;
our ability to maintain positive perception of our platform or maintain and enhance our brand; risks related to any failure to
maintain effective internal control over financial reporting; risks related to use of social media, emails, text messages, and
other messaging channels as part of our marketing strategy; our dependence on our information technology systems and
those of our third-party vendors, and risks related to any failure or significant disruptions thereof; risks related to government
regulation of the internet, e-commerce, consumer data and privacy, information technology, and cybersecurity; risks related
to the use of AI and machine learning in our business; risks related to a decrease in consumer willingness to receive
correspondence or any technical, legal, or any other restrictions to send such correspondence; risks related to any failure to
comply with applicable data protection, privacy and security, advertising and consumer protection laws, regulations,
standards, and other requirements; our ability to utilize our net operating loss carryforwards and certain other tax attributes;
the risk that we may be unable to realize expected benefits from our restructuring and cost reduction efforts; our ability to
attract, develop, motivate and retain well-qualified employees; risks related to our acquisition strategy; risks related to our
debt arrangements; interruptions or delays in service on our apps or websites or any undetected errors or design faults; our
reliance on third-party platforms to distribute our platform and offerings, including software as-a-service technologies;
systems failures or other disruptions in the operations of these parties on which we depend; risks related to climate change;
risks associated with environmental sustainability and social initiatives; risks related to our intellectual property; risks related
to operating in the healthcare industry; risks related to our organizational structure; litigation related risks; our ability to
accurately forecast revenue and appropriately plan our expenses in the future; risks related to general economic factors,
natural disasters, or other unexpected events; risks related to fluctuations in our tax obligations and effective income tax rate
which could materially and adversely affect our results of operations; risks related to the healthcare reform legislation and
other proposed or future changes impacting the healthcare industry and healthcare spending, including the new platform
TrumpRx, which may adversely affect our business, financial condition and results of operations; as well as the other
important factors discussed in the section entitled “Risk Factors” of our Annual Report on Form 10-K for the fiscal year
ended December 31, 2025 and in our other filings with the Securities and Exchange Commission. The forward-looking
statements in this press release are based upon information available to us as of the date of this press release, and while
we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete,
and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all
potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to
unduly rely upon these statements. While we may elect to update such forward-looking statements at some point in the
future, we disclaim any obligation to do so, even if subsequent events cause our views to change.
Exhibit 99.1
a1a.jpg
Key Operating Metrics
Monthly Active Consumers (MACs) refers to the number of unique consumers who have used a GoodRx code to purchase a
prescription medication in a given calendar month and have saved money compared to the list price of the medication. A
unique consumer who uses a GoodRx code more than once in a calendar month to purchase prescription medications is
only counted as one Monthly Active Consumer in that month. A unique consumer who uses a GoodRx code in two or three
calendar months within a quarter will be counted as a Monthly Active Consumer in each such month. Monthly Active
Consumers do not include subscribers to our subscription offerings, consumers of our Pharma Direct offering, or consumers
who used our telehealth offering. When presented for a period longer than a month, Monthly Active Consumers are
averaged over the number of calendar months in such period. Monthly Active Consumers from acquired companies are
included beginning from the acquisition date. As our business continues to evolve, we are reassessing the Monthly Active
Consumers metric as a primary indicator of performance to ensure it aligns with how we measure growth and profitability.
Subscription plans represent the ending subscription plan balance across our subscription offerings, GoodRx Gold,
condition-specific related subscription programs (first launched in June 2025), RxSmartSaver+ powered by GoodRx
(launched in July 2025) and GoodRx Companion (monthly and annual plans launched in May and July 2026, respectively).
For GoodRx Gold and RxSmartSaver+, each subscription plan may represent more than one subscriber since family
subscription plans may include multiple members.
Three Months Ended
(in millions)
June 30,
2026
March 31,
2026
December 31,
2025
September 30,
2025
June 30,
2025
March 31,
2025
Monthly Active Consumers
5.0
5.3
5.3
5.4
5.7
6.4
As of
(in thousands)
June 30,
2026
March 31,
2026
December 31,
2025
September 30,
2025
June 30,
2025
March 31,
2025
Subscription plans
764
717
674
671
668
680
Exhibit 99.1
a1a.jpg
GoodRx Holdings, Inc.
Condensed Consolidated Balance Sheets (Unaudited)
(in thousands, except par values)
June 30, 2026
December 31, 2025
Assets
Current assets
Cash and cash equivalents
$296,113
$261,820
Accounts receivable, net
182,140
235,746
Prescription reimbursement assets
1,076,012
98,331
Prepaid expenses and other current assets
45,062
47,205
Total current assets
1,599,327
643,102
Property and equipment, net
11,514
12,268
Goodwill
430,331
430,331
Intangible assets, net
58,254
64,082
Capitalized software, net
140,300
139,261
Operating lease right-of-use assets, net
27,630
28,808
Deferred tax assets, net
47,335
57,111
Other assets
28,237
29,095
Total assets
$2,342,928
$1,404,058
Liabilities and stockholders' equity
Current liabilities
Accounts payable
$8,906
$19,405
Prescription reimbursement liabilities
1,039,995
130,139
Accrued expenses and other current liabilities
98,610
86,705
Current portion of debt
5,000
5,000
Operating lease liabilities, current
5,358
4,753
Total current liabilities
1,157,869
246,002
Debt, net
481,588
483,264
Operating lease liabilities, net of current portion
47,004
49,789
Other liabilities
8,866
8,741
Total liabilities
1,695,327
787,796
Stockholders' equity
Preferred stock, $0.0001 par value
—
—
Common stock, $0.0001 par value
34
34
Additional paid-in capital
2,048,436
2,026,802
Accumulated deficit
(1,400,869)
(1,410,574)
Total stockholders' equity
647,601
616,262
Total liabilities and stockholders' equity
$2,342,928
$1,404,058
Exhibit 99.1
a1a.jpg
GoodRx Holdings, Inc.
Condensed Consolidated Statements of Operations (Unaudited)
(in thousands, except per share amounts)
Three Months Ended
June 30,
Six Months Ended
June 30,
2026
2025
2026
2025
Revenue
$200,411
$203,070
$394,417
$406,040
Costs and operating expenses:
Cost of revenue, exclusive of depreciation and
amortization presented separately below
20,999
13,350
41,155
26,714
Product development and technology
26,711
29,933
56,888
61,075
Sales and marketing
81,986
84,870
163,039
169,412
General and administrative
24,814
28,379
51,633
58,009
Depreciation and amortization
22,269
19,729
44,061
40,641
Total costs and operating expenses
176,779
176,261
356,776
355,851
Operating income
23,632
26,809
37,641
50,189
Other expense, net:
Other income
625
694
625
694
Interest income
1,019
2,803
2,416
6,735
Interest expense
(9,810)
(10,729)
(19,577)
(21,373)
Total other expense, net
(8,166)
(7,232)
(16,536)
(13,944)
Income before income taxes
15,466
19,577
21,105
36,245
Income tax expense
(6,930)
(6,734)
(11,400)
(12,350)
Net income
$8,536
$12,843
$9,705
$23,895
Earnings per share:
Basic
$0.03
$0.04
$0.03
$0.06
Diluted
$0.02
$0.04
$0.03
$0.06
Weighted average shares used in computing
earnings per share:
Basic
339,277
356,623
339,839
367,847
Diluted
348,058
357,159
344,676
368,345
Stock-based compensation included in costs and
operating expenses:
Cost of revenue
$58
$122
$110
$222
Product development and technology
4,554
6,323
8,762
11,993
Sales and marketing
4,203
5,929
8,452
11,811
General and administrative
7,778
9,041
15,778
16,563
Exhibit 99.1
a1a.jpg
GoodRx Holdings, Inc.
Condensed Consolidated Statements of Cash Flows (Unaudited)
(in thousands)
Six Months Ended
June 30,
2026
2025
Cash flows from operating activities
Net income
$9,705
$23,895
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization
44,061
40,641
Amortization of debt issuance costs and discounts
932
869
Non-cash operating lease expense
1,910
2,065
Stock-based compensation expense
33,102
40,589
Deferred income taxes
9,776
—
Loss on operating lease asset
—
4,409
Other
1,069
456
Changes in operating assets and liabilities:
Accounts receivable
53,606
(43,093)
Prescription reimbursement assets (1)
(977,681)
(16,027)
Prepaid expenses and other assets (1)
2,929
231
Accounts payable (1)
(9,871)
3,579
Prescription reimbursement liabilities (1)
909,856
(1,313)
Accrued expenses and other current liabilities (1)
16,063
5,585
Operating lease liabilities
(2,912)
(3,187)
Other liabilities
125
294
Net cash provided by operating activities
92,670
58,993
Cash flows from investing activities
Purchase of property and equipment
(1,498)
(532)
Acquisition
—
(30,000)
Capitalized software
(34,555)
(39,659)
Net cash used in investing activities
(36,053)
(70,191)
Cash flows from financing activities
Payments on long-term debt
(2,500)
(2,500)
Repurchases of Class A common stock
(14,520)
(145,888)
Proceeds from exercise of stock options
95
3
Employee taxes paid related to net share settlement of equity awards
(5,768)
(8,305)
Proceeds from employee stock purchase plan
369
860
Net cash used in financing activities
(22,324)
(155,830)
Net change in cash and cash equivalents
34,293
(167,028)
Cash and cash equivalents
Beginning of period
261,820
448,346
End of period
$296,113
$281,318
_____________________________________________________
(1)Prior to December 31, 2025, prescription reimbursement assets were presented as a component of prepaid
expenses and other current assets, and prescription reimbursement liabilities as a component of accounts payable
and accrued expenses and other current liabilities. Prior period amounts have been reclassified to conform to the
current period presentation. These reclassifications had no impact on previously reported cash flows provided by
operating activities.
Exhibit 99.1
a1a.jpg
For the three and six months ended June 30, 2026 and 2025, revenue comprised of the following:
(in thousands)
Three Months Ended
June 30,
Six Months Ended
June 30,
2026
2025
2026
2025
Prescription transactions revenue
$106,390
$143,064
$220,082
$291,987
Subscription revenue
28,514
20,463
52,907
41,480
Pharma Direct revenue
61,628
34,981
113,858
63,629
Other revenue
3,879
4,562
7,570
8,944
Total revenue
$200,411
$203,070
$394,417
$406,040
Exhibit 99.1
a1a.jpg
Non-GAAP Financial Measures
Adjusted Revenue and metrics presented as a percentage of Adjusted Revenue, Adjusted EBITDA, Adjusted EBITDA
Margin, Adjusted Net Income, Adjusted Net Income Margin, and Adjusted Earnings Per Share are supplemental measures of
our performance that are not required by, or presented in accordance with, U.S. GAAP. We also present each cost and
operating expense on our condensed consolidated statements of operations on an adjusted basis to arrive at adjusted
operating income. Collectively, we refer to these non-GAAP financial measures as our “Non-GAAP Measures."
We define Adjusted Revenue for a particular period as revenue excluding client contract termination costs associated with
restructuring related activities. We exclude these costs from revenue because we believe they are not indicative of past or
future underlying performance of the business. For the current period and full year of 2025, revenue was equal to Adjusted
Revenue. In addition, we expect revenue for the full year of 2026 to equal Adjusted Revenue.
We define Adjusted EBITDA for a particular period as net income or loss before interest, taxes, depreciation and
amortization, and as further adjusted for, as applicable for the periods presented, acquisition related expenses, stock-based
compensation expense, payroll tax expense related to stock-based compensation, loss on extinguishment of debt, financing
related expenses, loss on operating lease assets, restructuring related expenses, legal settlement expenses, gain on sale of
business, and other income or expense, net. Adjusted EBITDA Margin represents Adjusted EBITDA as a percentage of
Adjusted Revenue.
We define Adjusted Net Income for a particular period as net income or loss adjusted for, as applicable for the periods
presented, amortization of intangibles related to acquisitions and restructuring activities, acquisition related expenses, stock-
based compensation expense, payroll tax expense related to stock-based compensation, loss on extinguishment of debt,
financing related expenses, loss on operating lease assets, restructuring related expenses, legal settlement expenses, gain
on sale of business, other income or expense, net, and as further adjusted for estimated income tax on such adjusted items.
Our adjusted taxes also exclude (i) the valuation allowance recorded against certain of our net deferred tax assets that was
recognized in accordance with GAAP and any subsequent releases of the valuation allowance, and (ii) all tax benefits/
expenses resulting from excess tax benefits/deficiencies in connection with stock-based compensation. Adjusted Net
Income Margin represents Adjusted Net Income as a percentage of Adjusted Revenue.
Adjusted Earnings Per Share is Adjusted Net Income attributable to common stockholders divided by weighted average
number of shares. The weighted average shares we use in computing Adjusted Earnings Per Share – basic is equal to our
GAAP weighted average shares – basic and the weighted average shares we use in computing Adjusted Earnings Per
Share – diluted is equal to either GAAP weighted average shares – basic or GAAP weighted average shares – diluted,
depending on whether we have adjusted net loss or adjusted net income, respectively.
We also assess our performance by evaluating each cost and operating expense on our condensed consolidated
statements of operations on a non-GAAP, or adjusted, basis to arrive at adjusted operating income. The adjustments to
these cost and operating expense items include, as applicable for the periods presented, acquisition related expenses,
amortization of intangibles related to acquisitions and restructuring activities, stock-based compensation expense, payroll
tax expense related to stock-based compensation, financing related expenses, restructuring related expenses, legal
settlement expenses, loss on operating lease assets, and gain on sale of business. Adjusted operating income is Adjusted
Revenue less non-GAAP costs and operating expenses.
We believe our Non-GAAP Measures are helpful to investors, analysts and other interested parties because they assist in
providing a more consistent and comparable overview of our operations across our historical financial periods. Adjusted
Revenue, Adjusted EBITDA, and Adjusted EBITDA Margin are also key measures we use to assess our financial
performance and are also used for internal planning and forecasting purposes. In addition, Adjusted Revenue, Adjusted
EBITDA, Adjusted EBITDA Margin, Adjusted Net Income, and Adjusted Earnings Per Share are frequently used by analysts,
investors and other interested parties to evaluate and assess performance.
The Non-GAAP Measures are presented for supplemental informational purposes only and should not be considered as
alternatives or substitutes to financial information presented in accordance with GAAP. These measures have certain
limitations in that they do not include the impact of certain costs that are reflected in our condensed consolidated statements
of operations that are necessary to run our business. Other companies, including other companies in our industry, may not
use these measures or may calculate these measures differently than as presented herein, limiting their usefulness as
comparative measures.
Exhibit 99.1
a1a.jpg
The following table presents a reconciliation of net income, the most directly comparable financial measure calculated in
accordance with GAAP, to Adjusted EBITDA, and presents net income margin, the most directly comparable financial
measure calculated in accordance with GAAP, with Adjusted EBITDA Margin:
(dollars in thousands)
Three Months Ended
June 30,
Six Months Ended
June 30,
2026
2025
2026
2025
Net income
$8,536
$12,843
$9,705
$23,895
Adjusted to exclude the following:
Interest income
(1,019)
(2,803)
(2,416)
(6,735)
Interest expense
9,810
10,729
19,577
21,373
Income tax expense
6,930
6,734
11,400
12,350
Depreciation and amortization
22,269
19,729
44,061
40,641
Other income
(625)
(694)
(625)
(694)
Acquisition related expenses
275
—
527
26
Restructuring related expenses
572
546
5,858
1,765
Legal settlement expenses
—
355
—
355
Stock-based compensation expense
16,593
21,415
33,102
40,589
Payroll tax expense related to stock-based compensation
399
549
821
1,234
Loss on operating lease asset
—
—
—
4,409
Adjusted EBITDA
$63,740
$69,403
$122,010
$139,208
Revenue
$200,411
$203,070
$394,417
$406,040
Net income margin
4.3%
6.3%
2.5%
5.9%
Adjusted EBITDA Margin
31.8%
34.2%
30.9%
34.3%
Exhibit 99.1
a1a.jpg
The following tables present a reconciliation of net income and calculations of net income margin and earnings per share,
the most directly comparable financial measures calculated in accordance with GAAP, to Adjusted Net Income, Adjusted Net
Income Margin, and Adjusted Earnings Per Share, respectively:
(dollars in thousands, except per share amounts)
Three Months Ended
June 30,
Six Months Ended
June 30,
2026
2025
2026
2025
Net income
$8,536
$12,843
$9,705
$23,895
Adjusted to exclude the following:
Amortization of intangibles related to acquisitions
and restructuring related activities
2,913
2,793
5,828
5,586
Other income
(625)
(694)
(625)
(694)
Acquisition related expenses
275
—
527
26
Restructuring related expenses
572
546
5,858
1,765
Legal settlement expenses
—
355
—
355
Stock-based compensation expense
16,593
21,415
33,102
40,589
Payroll tax expense related to stock-based
compensation
399
549
821
1,234
Loss on operating lease asset
—
—
—
4,409
Income tax effects of excluded items and
adjustments for valuation allowance and excess tax
benefits/deficiencies from equity awards
(1,879)
(3,904)
(5,383)
(8,899)
Adjusted Net Income
$26,784
$33,903
$49,833
$68,266
Revenue
$200,411
$203,070
$394,417
$406,040
Net income margin
4.3%
6.3%
2.5%
5.9%
Adjusted Net Income Margin
13.4%
16.7%
12.6%
16.8%
Weighted average shares used in computing
earnings per share:
Basic
339,277
356,623
339,839
367,847
Diluted
348,058
357,159
344,676
368,345
Earnings per share:
Basic
$0.03
$0.04
$0.03
$0.06
Diluted
$0.02
$0.04
$0.03
$0.06
Weighted average shares used in computing
Adjusted Earnings Per Share:
Basic
339,277
356,623
339,839
367,847
Diluted
348,058
357,159
344,676
368,345
Adjusted Earnings Per Share:
Basic
$0.08
$0.10
$0.15
$0.19
Diluted
$0.08
$0.09
$0.14
$0.19
Exhibit 99.1
a1a.jpg
The following table presents (i) each non-GAAP, or adjusted, cost and expense and operating income measure together with
its most directly comparable financial measure calculated in accordance with GAAP; and (ii) each adjusted cost and
expense and adjusted operating income as a percentage of Adjusted Revenue together with each GAAP cost and expense
and operating income as a percentage of revenue, the most directly comparable financial measure calculated in accordance
with GAAP:
(dollars in thousands)
GAAP
Adjusted
GAAP
Adjusted
Three Months Ended
June 30,
Three Months Ended
June 30,
Six Months Ended
June 30,
Six Months Ended
June 30,
2026
2025
2026
2025
2026
2025
2026
2025
Cost of revenue
$20,999
$13,350
$20,922
$13,234
$41,155
$26,714
$41,006
$26,492
% of Revenue
10%
7%
10%
7%
10%
7%
10%
7%
Product development and technology
$26,711
$29,933
$21,863
$23,500
$56,888
$61,075
$44,692
$47,490
% of Revenue
13%
15%
11%
12%
14%
15%
11%
12%
Sales and marketing
$81,986
$84,870
$77,515
$77,966
$163,039
$169,412
$152,599
$156,370
% of Revenue
41%
42%
39%
38%
41%
42%
39%
39%
General and administrative
$24,814
$28,379
$16,371
$18,967
$51,633
$58,009
$34,110
$36,480
% of Revenue
12%
14%
8%
9%
13%
14%
9%
9%
Depreciation and amortization
$22,269
$19,729
$19,356
$16,936
$44,061
$40,641
$38,233
$35,055
% of Revenue
11%
10%
10%
8%
11%
10%
10%
9%
Operating income
$23,632
$26,809
$44,384
$52,467
$37,641
$50,189
$83,777
$104,153
% of Revenue
12%
13%
22%
26%
10%
12%
21%
26%
Exhibit 99.1
a1a.jpg
The following table presents a reconciliation of each non-GAAP, or adjusted, cost and expense and operating income
measure to its most directly comparable financial measure calculated in accordance with GAAP:
(dollars in thousands)
Three Months Ended
June 30,
Six Months Ended
June 30,
2026
2025
2026
2025
Cost of revenue
$20,999
$13,350
$41,155
$26,714
Acquisition related expenses
(17)
—
(36)
—
Restructuring related expenses
—
12
—
10
Stock-based compensation expense
(58)
(122)
(110)
(222)
Payroll tax expense related to stock-based compensation
(2)
(6)
(3)
(10)
Adjusted cost of revenue
$20,922
$13,234
$41,006
$26,492
Product development and technology
$26,711
$29,933
$56,888
$61,075
Acquisition related expenses
(89)
—
(175)
—
Restructuring related expenses
—
202
(2,872)
(907)
Stock-based compensation expense
(4,554)
(6,323)
(8,762)
(11,993)
Payroll tax expense related to stock-based compensation
(205)
(312)
(387)
(685)
Adjusted product development and technology
$21,863
$23,500
$44,692
$47,490
Sales and marketing
$81,986
$84,870
$163,039
$169,412
Acquisition related expenses
(169)
—
(316)
—
Restructuring related expenses
—
(848)
(1,479)
(935)
Stock-based compensation expense
(4,203)
(5,929)
(8,452)
(11,811)
Payroll tax expense related to stock-based compensation
(99)
(127)
(193)
(296)
Adjusted sales and marketing
$77,515
$77,966
$152,599
$156,370
General and administrative
$24,814
$28,379
$51,633
$58,009
Acquisition related expenses
—
—
—
(26)
Restructuring related expenses
(572)
88
(1,507)
67
Legal settlement expenses
—
(355)
—
(355)
Stock-based compensation expense
(7,778)
(9,041)
(15,778)
(16,563)
Payroll tax expense related to stock-based compensation
(93)
(104)
(238)
(243)
Loss on operating lease asset
—
—
—
(4,409)
Adjusted general and administrative
$16,371
$18,967
$34,110
$36,480
Depreciation and amortization
$22,269
$19,729
$44,061
$40,641
Amortization of intangibles related to acquisition
(2,913)
(2,793)
(5,828)
(5,586)
Adjusted depreciation and amortization
$19,356
$16,936
$38,233
$35,055
Operating income
$23,632
$26,809
$37,641
$50,189
Amortization of intangibles related to acquisition
2,913
2,793
5,828
5,586
Acquisition related expenses
275
—
527
26
Restructuring related expenses
572
546
5,858
1,765
Legal settlement expenses
—
355
—
355
Stock-based compensation expense
16,593
21,415
33,102
40,589
Payroll tax expense related to stock-based compensation
399
549
821
1,234
Loss on operating lease asset
—
—
—
4,409
Adjusted operating income
$44,384
$52,467
$83,777
$104,153

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

4 documents

Press Releases

Other Documents

Keep reading

More on GDRX

Trending in the feed

Open the live feed